Literature DB >> 9670952

NK cells can recognize different forms of class I MHC.

R C Su1, S K Kung, J Gariépy, B H Barber, R G Miller.   

Abstract

NK recognition and lysis of targets are mediated by activation receptor(s) whose effects may be over-ridden by inhibitory receptors recognizing class I MHC on the target. Incubation of normal lymphoblasts with a peptide that can bind to their class I MHC renders them sensitive to lysis by syngeneic NK cells. By binding to class I MHC, the peptide alters or masks the target structure recognized by an inhibitory NK receptor(s). This target structure is most likely an "empty" dimer of class I heavy chain and beta2m as opposed to a "full" class I trimer formed by binding of specific peptide that is recognized by CTL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9670952

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

Review 1.  Optimizing intracellular signaling domains for CAR NK cells in HIV immunotherapy: a comprehensive review.

Authors:  Giorgio Zenere; Omalla Allan Olwenyi; Siddappa N Byrareddy; Stephen E Braun
Journal:  Drug Discov Today       Date:  2019-02-13       Impact factor: 7.851

2.  Natural killer cells and Helicobacter pylori infection: bacterial antigens and interleukin-12 act synergistically to induce gamma interferon production.

Authors:  Cheol H Yun; Anna Lundgren; Josef Azem; Asa Sjöling; Jan Holmgren; Ann-Mari Svennerholm; B Samuel Lundin
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

Review 3.  Homotypic and heterotypic in cis associations of MHC class I molecules at the cell surface.

Authors:  Fernando M Ruggiero; Sebastian Springer
Journal:  Curr Res Immunol       Date:  2022-05-23

4.  Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19.

Authors:  Ting Lu; Rui Ma; Wenjuan Dong; Kun-Yu Teng; Daniel S Kollath; Zhiyao Li; Jinhee Yi; Christian Bustillos; Shoubao Ma; Lei Tian; Anthony G Mansour; Zhenlong Li; Erik W Settles; Jianying Zhang; Paul S Keim; Bridget M Barker; Michael A Caligiuri; Jianhua Yu
Journal:  Nat Commun       Date:  2022-05-11       Impact factor: 17.694

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.